Certified Nurse-Midwife Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Holt

Advanced Practice Midwife Atlanta, GA Certified Nurse-Midwife

NPI 1093974784 CMS profile 11149796

#9 Dunwoody Park, Suite 108 Arbor Ob Gyn, Atlanta, GA 30338

Open in the dashboard

General payments

$1,514

82 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Holt of Atlanta, GA is reported in the CMS Open Payments database as having received $1,514 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $259 15
2024 General $210 12
2023 General $342 17
2022 General $315 16
2021 General $388 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Holt
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Lisa Holt were reported at $259. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Lisa Holt Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $388 $57 $22–$142 $132
2022 $315 $61 $23–$157 $149
2023 $342 $68 $26–$167 $160
2024 $210 $63 $25–$142 $164
2025 $259 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $424 22 payments
  2. Evofem Biosciences, Inc. $167 9 payments
  3. Mayne Pharma Inc. $92 8 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $79 4 payments
  5. Myovant Sciences Inc. $78 5 payments
  6. Sumitomo Pharma America, Inc. $74 5 payments
  7. Astellas Pharma US Inc $72 4 payments
  8. Channel Medsystems, Inc. $66 1 payment
  9. Millicent US Inc $66 3 payments
  10. Shield Therapeutics Inc $61 3 payments
  11. Other $337 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,514 82 payments
Products named General payments · program years 2021–2025
  1. LO LOESTRIN FE $293 14 payments
  2. MYFEMBREE $151 10 payments
  3. ORILISSA $127 8 payments
  4. ORIAHNN $125 7 payments
  5. Mirena $79 4 payments
  6. Kyleena $79 4 payments
  7. Phexxi $76 3 payments
  8. Veozah $72 4 payments
  9. ACCRUFER $61 3 payments
  10. VIVIFY HEALTH CARE TEAM PORTAL 001 $53 2 payments
  11. Other $676 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Certified Nurse Midwife: 28

Drug cost

$2,919

Median for Certified Nurse Midwife: $1,314

Branded share of claims

100%

Median for Certified Nurse Midwife: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Intrarosa Prasterone (Dhea) Brand 11 $2,919

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,212 Part D prescribers listed as Certified Nurse Midwife; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $36
$36 — —
SLYND
  • Exeltis, USA Inc. $22
$22 — —
INTRAROSA
  • MILLICENT US INC $21
$21 11 —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $17
$17 — —
ABRYSVO
  • PFIZER INC. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record